AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CRISPR Therapeutics AG Director's Dealing 2018

Dec 21, 2018

30936_dirs_2018-12-21_cb814004-6155-41eb-9e40-c3f7ce36804b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2018-12-20

Reporting Person: Vertex Pharmaceuticals (Europe) Ltd (10% Owner)
Reporting Person: VERTEX PHARMACEUTICALS INC / MA (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares	5250000	Direct

Footnotes

F1: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe.